Sarah Ackroyd, MD MPH

A cell atlas of the human fallopian tube throughout the menstrual cycle and menopause.
A cell atlas of the human fallopian tube throughout the menstrual cycle and menopause. Nat Commun. 2025 Jan 03; 16(1):372.
PMID: 39753552

Geographic and racial disparities in the quality of surgical care among patients with nonmetastatic uterine cancer.
Geographic and racial disparities in the quality of surgical care among patients with nonmetastatic uterine cancer. Am J Obstet Gynecol. 2025 Mar; 232(3):308.e1-308.e15.
PMID: 39245428

The burden of cervical cancer survivorship: Understanding morbidity and survivorship needs through hospital admissions.
The burden of cervical cancer survivorship: Understanding morbidity and survivorship needs through hospital admissions. Gynecol Oncol Rep. 2024 Feb; 51:101328.
PMID: 38318201

A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing.
A molecular atlas of the human postmenopausal fallopian tube and ovary from single-cell RNA and ATAC sequencing. Cell Rep. 2022 12 20; 41(12):111838.
PMID: 36543131

Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma.
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. Gynecol Oncol. 2023 02; 169:164-171.
PMID: 36333181

Surviving and thriving: What do survivors of gynecologic cancer want?
Surviving and thriving: What do survivors of gynecologic cancer want? Gynecol Oncol Rep. 2022 Jun; 41:101011.
PMID: 35663850

Lessons learned: Telemedicine patterns and clinical application in patients with gynecologic cancers during COVID-19.
Lessons learned: Telemedicine patterns and clinical application in patients with gynecologic cancers during COVID-19. Gynecol Oncol Rep. 2022 Jun; 41:100986.
PMID: 35540027

A look at the gynecologic oncologist workforce - Are we meeting patient demand?
A look at the gynecologic oncologist workforce - Are we meeting patient demand? Gynecol Oncol. 2021 11; 163(2):229-236.
PMID: 34456058

"The promise and vulnerability of telemedicine".
"The promise and vulnerability of telemedicine". Gynecol Oncol. 2021 07; 162(1):1-3.
PMID: 34154727

Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
PMID: 34103196